Established at the end of 2024, AISRI originated from a key incubated project within the listed company Tianzhihang. Leveraging Tianzhihang’s profound patented technologies and accumulated clinical data of surgical robots, it focuses on building an intelligent diagnosis and treatment ecosystem centered on precise intraoperative imaging. Committed to providing patients with efficient, intelligent diagnosis and treatment solutions that are minimally invasive, precise and personalized, AISRI fulfills its corporate vision: “With our expertise, we safeguard the beauty of life.”